ISPOR

Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses his appreciation for telehealth and remote care, but feels over the next year or so we're going to be seeing more studies come out questioning if some telehealth is needed in certain areas. The discussion came from findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research.

Amy Abernethy, M.D., Ph.D., hematologist/oncologist and palliative medicine physician and former principal deputy commissioner of the FDA, discusses how the agency handled COVID-19 and what lessons learned will help going forward. Abernethy also addresses if she feels there are enough safeguards of the FDA's independence in place, and reflects on the open FDA commissioner position.

Panelists at 2021 ISPOR say price shouldn't be barrier. Suggestions include steep payment discounts if therapies don't meet outcome goals and regulators removing withdrawing approvals if the therapy doesn't work.

It shouldn’t be just about QALYs and cost. An ISPOR panel today discussed how best to incorporate the patient perspective into value assessment.

Dr. Vivian Lee of Verily Life Sciences addresses if value-based care programs have steered U.S healthcare away from the problems of fee-for-service at a virtual ISPOR meeting today. Lee also shares her thoughts on if the pandemic changed her views of American healthcare.